Sana Biotechnology (SANA) Stock
Biotechnology company developing cell and gene therapy platforms. Here's the price, business snapshot, and what's worth knowing about Sana Biotechnology in July 2026.
Sana Biotechnology Inc (SANA) is a clinical-stage biotechnology company developing platform technologies for cell and gene therapies. The firm pursues both in vivo and ex vivo approaches to engineer cells for treating a range of diseases, and its valuation—around $1.4 billion market cap—reflects investor expectations for future clinical progress. Key things an investor should know include the stage of the pipeline, upcoming trial readouts and regulatory milestones, partnerships and manufacturing scale-up, and the company’s cash runway and financing needs. Biotechnology investing is high risk and outcomes can be binary: positive clinical data can materially increase value, while setbacks can lead to significant share price declines. This summary is general educational information and not personalised investment advice; investors should conduct their own research and consider seeking professional financial guidance before acting.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying SANA Biotechnology's stock with a target price of $9.40, indicating potential growth.
Financial Health
Sana Biotechnology is managing its finances reasonably well, with decent cash flow and book value.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring SANA
Ozempic Price Pressure | Pharma Investment Shift
A recent announcement of plans to slash prices for major weight-loss drugs has created turmoil for market leaders Novo Nordisk and Eli Lilly. This theme explores the investment opportunities that arise for competing pharmaceutical companies and developers of alternative treatments who may benefit from this market disruption.
Published: 21 October 2025
Explore BasketHope & Optimism Portfolio
This collection brings together pioneering companies working to solve humanity's biggest challenges through groundbreaking innovation. These carefully selected stocks represent visionaries building transformative technologies in medicine, energy, and beyond.
Published: 18 June 2025
Explore BasketAge-Reversal Biotech
Invest in pioneering companies that are redefining aging as a treatable condition. These carefully selected biotechs are developing groundbreaking therapies to extend healthy lifespans and potentially reverse cellular damage, creating an entirely new frontier in medicine.
Published: 17 June 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts Ahead
Several clinical readouts and preclinical milestones could materially affect valuation, though outcomes are uncertain and performance can vary.
Platform Innovation Focus
Sana’s in vivo and ex vivo platforms aim to improve delivery and manufacturability, which may offer competitive advantages but are not guaranteed to produce approved therapies.
Partnerships and Scale
Collaborations and manufacturing scale-up can derisk development and expand reach, yet they require capital and regulatory alignment and may take time.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
